Advertisement Tigermed and Qiming join hands to grant asset injection to MacroStat - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Tigermed and Qiming join hands to grant asset injection to MacroStat

Tigermed Consulting, a contract research organization, or CRO, in China, and Qiming Venture, a venture capital firm based in Shanghai, have joined hands to grant asset injection to MacroStat, a CRO engaged in clinical data management and statistical analysis.

The union between the two CROs will significantly improve Tigermed’s clinical data management serviceability and broaden MacroStat’s business line, said Tigermed.

Ye Xiaoping, CEO and founder of Tigermed, said: “MacroStat has the leading talents and system in biostatistics, with absolute competitive advantage in China. Tigermed and MacroStat shall establish extensive strategic partnership in the management of clinical trials, data management and statistical analysis.

“Tigermed accumulated outstanding expertise in clinical trials, while MacroStat is an expert in biostatistics. Our co-operation shall expand Tigermed’s business line and add professionalism to Tigermed’s biostatistics services.”